Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III iressa pan-ASia study (IPASS)

Lung Cancer

Volumn 83, Issue 2, 2014, Pages 174-181

  Yang, James Chih Hsin ^a   Wu, Yi Long ^b   Chan, Valorie ^c   Kurnianda, Johan ^d   Nakagawa, Kazuhiko ^e   Saijo, Nagahiro ^f   Fukuoka, Masahiro ^e   McWalter, Gael ^g   McCormack, Rose ^g   Mok, Tony S K ^h  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c Veterans Memorial Medical Center   (Philippines)

^d Sardjito Hospital   (Indonesia)

^e KINKI UNIVERSITY   (Japan)

^f KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g ASTRAZENECA   (United Kingdom)

^h CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cytology; Diagnostic; EGFR; Histology; Mutation; NSCLC; Tumor

Indexed keywords

CARBOPLATIN; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PACLITAXEL;

ARTICLE; CANCER CHEMOTHERAPY; CYTOLOGY; DNA DETERMINATION; EXON; GENE MUTATION; HISTOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MUTATION RATE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR VOLUME;

CYTOLOGY; DIAGNOSTIC; EGFR; HISTOLOGY; MUTATION; NSCLC; TUMOR;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DNA MUTATIONAL ANALYSIS; EARLY DETECTION OF CANCER; HISTOLOGICAL TECHNIQUES; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MUTATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84892880551     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.11.021     Document Type: Article

References (20)

1. Azzoli C.G., Baker S., Temin S., Pao W., Aliff T., Brahmer J., et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009, 27:6251-6266.
2. Azzoli C.G., Temin S., Aliff T., Baker S., Brahmer J., Johnson D.H., et al. 2011 focused update of 2009 American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2011, 29:3825-3831.
3. Kris M.G., Johnson B.E., Kwiatkowski D.J., Lafrate A.J., Witsuba I.I., Aronson S.L., et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: the NCI's lung cancer mutation consortium (LCMC). J Clin Oncol 2011, 29(Suppl.). [abstract CRA7506].
4. Fukuoka M., Wu Y.-L., Thongprasert S., Sunpaweravong P., Leong S.-S., Sriuranpong V., et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011, 29:2866-2874.
5. Mok T.S., Wu Y.-L., Thongprasert S., Yang C.-H., Chu D.-T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
6. Han J.Y., Park K., Kim S.W., Lee D.H., Kim H.Y., Kim H.T., et al. First-SIGNAL: first-line single-agent Iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 2012, 30:1122-1128.
7. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
8. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11:121-128.
9. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13:239-246.
10. Sequist L.V., Yang J.C.H., Yamamoto N., O'Byrne K.J., Hirsh V., Mok T.S.K., et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013, 3327-3334. 10.1200/JCO.2012.44.2806.
11. Zhou C., Wu Y.-L., Chen G., Feng J., Liu X.-Q., Wang C., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12:735-742.
12. Hlinkova K., Babal P., Berzinec P., Majer I., Mikle-Barathova Z., Piackova B., et al. Evaluation of 2-year experience with EGFR mutation analysis of small diagnostic samples. Diagn Mol Pathol 2013, 22:70-75.
13. Smouse J.H., Cibas E.S., Janne P.A., Joshi V.A., Zou K.H., Lindeman N.I. EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. Cancer 2009, 117:67-72.
14. Hagiwara K., Kobayashi K. Importance of the cytological samples for the epidermal growth factor receptor gene mutation test for non-small cell lung cancer. Cancer Sci 2013, 104:291-297.
15. D'Addario G., Früh M., Reck M., Baumann P., Klepetko W., Felip E. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl. 5):v116-v119.
16. Keedy V.L., Temin S., Somerfield M.R., Beasley M.B., Johnson D.H., McShane L.M., et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 2011, 29:2121-2127.
17. Eberhard D.A., Giaccone G., Johnson B.E. Biomarkers of response to epidermal growth factor receptor inhibitors in non-small-cell lung cancer working group: standardization for use in the clinical trial setting. J Clin Oncol 2008, 26:983-994.
18. Marchetti A., Normanno N., AIOM-SIAPEC-IAP, Pinto C., Taddei G.L., Adamo V., et al. Recommendations for mutational analysis of EGFR in lung carcinoma. Pathologica 2010, 102:119-122.
19. Pirker R., Herth F.J., Kerr K.M., Filipits M., Taron M., Gandara D., et al. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol 2010, 5:1706-1713.
20. Salto-Tellez M., Tsao M.S., Shih J.Y., Thongprasert S., Lu S., Chang G.C., et al. Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approach. J Thorac Oncol 2011, 6:1663-1669.